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Conversion (functional) limb weakness or paralysis (FW) can be a debilitating condition,
and often causes significant distress or impairment in social, occupational, or other
important areas of functioning. Most treatment concepts are multi-disciplinary, containing
a behavioral approach combined with a motor learning program. Non-invasive brain
stimulation (NIBS) methods, such as electroconvulsive therapy (ECT), and transcranial
magnetic stimulation (TMS) have been used in the past few decades to treat FW.
In order to identify all published studies that used NIBS methods such as ECT,
TMS and transcranial direct current stimulation (tDCS) for treating FW patients a
systematic review of the literature was conducted in PubMed and Web of Science. In
a second step, narratives were used to retrospectively determine nominal CGI-I (Clinical
Global Impression scale–Improvement) scores to describe approximate changes of FW
symptoms. We identified two articles (case reports) with ECT used for treatment of
FW, five with TMS with a total of 86 patients, and none with tDCS. In 75 out of 86
patients treated with repetitive (r)TMS a nominal CGI-I score could be estimated, showing
a satisfactory short-term improvement. Fifty-four out of seventy-five identified patients
(72%) had a CGI-I score of 1 (very much improved), 13 (17%) a score of 2 (much
improved), 5 (7%) a score of 3 (minimally improved), and 3 (5%) remained unchanged
(CGI-I = 4). In no case did patients worsen after rTMS treatment, and no severe adverse
effects were reported. At follow-up, symptom improvement was not quantifiable in terms
of CGI-I for the majority of the cases. Patients treated with ECT showed a satisfactory
short-term response (CGI-I= 2), but deterioration of FW symptoms at follow-up. Despite
the predominantly positive results presented in the identified studies and satisfactory
levels of efficacy measured with retrospectively calculated nominal CGI-I scores, any
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assumption of a beneficial effect of NIBS in FW has to be seen with caution, as only few
articles could be retrieved and their quality was mostly poor. This article elucidates how
NIBS might help in FW and gives recommendations for future study designs using NIBS
in this condition.
Keywords: hysterical paralysis, hysterical neuroses, medically unexplained motor symptoms, functional
neurological disorder, functional lesion, psychogenic movement disorders, magnetic stimulation, electroshock
INTRODUCTION
Conversion Disorder is a frequent condition. It is classed under
“dissociative and conversion disorders” in the international
WHO-classification (WHO ICD-10, 1991) and “Functional
Neurological Symptom Disorder (FNS)” in DSM-5 (DSM-5,
2013). The precise prevalence of the disorder is unknown.
The reported incidence is between 4 and 12 cases per 100,000
habitants/year (DSM-5, 2013). In the largest prospective cohort
study, conversion disorder accounted for 5.6% of 3781 Scottish
patients referred from primary care to a National Health Service
neurology clinic (Stone et al., 2009).
Conversion (functional) weakness or paralysis (FW) [DSM-
5 300.11/ICD-10 F44.4], a subgroup of FNS that affect limbs,
can be very incapacitating and causes significant distress or
impairment in social, occupational, or other important areas
of functioning (Table 1 for DSM-5 criteria). In FW, symptoms
either cannot be explained by a neurological condition (or
other general medical condition), or clinical findings are
inconsistent with recognized neurological or medical disease
(DSM-5, 2013). Therefore, in the literature, such disorders have
been referred to as “psychogenic,” “hysterical,” “non-organic”.
or rather unfortunately, “pseudo-neurological” (Nowak and
Fink, 2009). The underlying etiological mechanisms involved
remain unclear. Psychological factors were required in DSM-
IV (former criterion B: “Psychological factors are judged to be
associated with the symptom or deficit because the initiation or
exacerbation of the symptom or deficit is preceded by conflicts
or other stressors”; Carson et al., 2012). This criterion has
been removed in DSM-5. Although conflicts and stressors may
influence patients’ vulnerability there is increasing evidence for
a neurobiological component in the etiology of FW (Liepert
et al., 2008, 2009, 2011). Over the last decade, neuroimaging
findings examining differential brain activity in FW have started
to support a neuro-biological hypothesis (Marshall et al., 1997;
Spence et al., 2000; Vuilleumier et al., 2001; Vuilleumier, 2005;
Burgmer et al., 2006; Stone et al., 2007; de Lange et al., 2008;
Cojan et al., 2009; van Beilen et al., 2011; Ludwig et al.,
2015), for review (Nowak and Fink, 2009). Even if the disorder
is sometimes not easy to differentiate from simulation or
malingering in a phenomenological way, FW is different from
a neurobiological point of view and shares similarities with
hypnotically induced paralysis (Bell et al., 2011; Ludwig et al.,
2015).
FW affecting limbs may be transient but can persist. The
socio-economic disease-burden is significant because of direct
treatment costs and the consequences of an often-permanent
loss of limb function leading to incapacity-related benefits
(Carson et al., 2011). In the past years, various treatment
strategies have been tested in FW related symptoms, including
different forms of physiotherapy (for review Nielsen et al.,
2013), pharmacotherapy (Rampello et al., 1996; Voon and
Lang, 2005), behavioral therapy (Shapiro and Teasell, 2004),
and hypnotherapy (Moene et al., 2002). The reported symptom
recovery is very heterogeneous and varies depending on the
treatment strategy and study. A large amount of new studies
reported marked short-term improvements, mostly in the region
of a 60–70% symptom reduction (Nielsen et al., 2013). However,
long-term outcome, especially in patients with a long duration
of illness at presentation is invariably poor (Feinstein et al.,
2001). Factors related to patient beliefs and disease concepts often
generate difficulties in the treatment of FW. UK neurologists
TABLE 1 | DSM-5 diagnostic criteria for Conversion Disorder (Functional
Neurological Symptom Disorder/FNS).
A. One or more symptoms or altered voluntary motor or sensory function.
B. Clinical findings provide evidence of incompatibility between the symptom and
recognized neurological or medical condition.
C. The symptom or deficit is not better explained by another medical or mental
disorder.
D. The symptom or deficit causes clinically significant distress or impairment in
social, occupational, or other important areas of functioning or warrants medical
evaluation.
Coding note: The ICD-9-CM code for conversion disorder is 300.11, which is
assigned regardless of the symptom type. The ICD-10-CM codes depends on
the symptom type (see below).
Specify symptom type:
• (F44.4) With weakness or paralysis
• (F44.4) With abnormal movement (e.g., tremor, dystonic movement,
myoclonus, gait disorder)
• (F44.4) With swallowing symptoms
• (F44.4) With speech symptoms (e.g., dysphonia, slurred speech)
• (F44.5) With attacks or seizures
• (F44.6) With anesthesia or sensory loss
• (F44.6) With special sensory symptoms
• (F44.7) With mixed symptoms
Specify if:
Acute episode: Symptoms present for <6 months.
Persistent: Symptoms occurring for 6 months or more.
Specify if:
With psychological stressor (specify stressor).
Without psychological stressor.
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describe patients with FNS as being “the most difficult to help”
(Carson et al., 2004). Although there is no agreement on the
most effective therapy for FW, most treatment concepts contain
at least two components: a behavioral approach and a motor
learning program using a multidisciplinary team (Nielsen et al.,
2013).
Non-invasive brain stimulation (NIBS) methods, such
as electroconvulsive therapy (ECT), transcranial magnetic
stimulation (TMS), and transcranial direct current stimulation
(tDCS), have been used in the past decades to treat various
mental disorders and may show beneficial effects in FW
symptoms:
(1) ECT, which was experimentally developed in the late 1930s
(Cerletti, 1940) was the first NIBS method to become
established within the framework of psychiatry. Based on
an electrically induced generalized seizure ECT is used for
the treatment of various mental disorders including affective
and schizophrenia spectrum disorders, and is considered the
most effective treatment in major depression (Taylor, 2008).
(2) TMS is a non-convulsive NIBS method, which was initially
developed for diagnostic purposes in order tomeasuremotor
latencies in the 1980s (Barker et al., 1985), and rapidly
expanded in its repetitive form (rTMS) to a treatment
strategy in the early 1990s. In 2010, the American FDA
approved it for the treatment of therapy-resistant major
depression in adults, although the clinical relevance of
its efficacy remains doubtful (Schönfeldt-Lecuona et al.,
2010; Lepping et al., 2014). The American Psychiatric
Association (APA), the Canadian Network for Mood and
Anxiety Treatments (CANMAT), and the World Federation
of Societies of Biological Psychiatry (WFSBP) have accepted
it as a treatment option for depression. It has been
tested experimentally in other neuropsychiatric conditions
(Lefaucheur et al., 2014).
(3) tDCS is based on a homogeneous electrical field at direct
current (DC) intensities of around 1 mA applied trans-
cranially to accessible cortical areas (Nitsche and Paulus,
2011). tDCS induces long-lasting cortical changes and thus
can be used to manipulate brain excitability via membrane
polarization. The induced after-effects depend on polarity,
duration and intensity of the stimulation (Paulus, 2011).
tDCS is still an experimental treatment method in psychiatry
but has demonstrated potential therapeutic efficacy in
different conditions (Koops et al., 2015; Meron et al., 2015;
Saba et al., 2015).
The exact mechanism of action of any of these NIBS methods
on cortical networks is not yet comprehensively understood.
However, it is known, that ECT facilitates the release of brain
derived neurotrophic factor (BDNF) (Polyakova et al., 2015). It
causes enlargement of hippocampal (and other) regions, possibly
through boosting neurogenesis (Nordanskog et al., 2014). rTMS
and tDCS have been shown to induce long-lasting changes in
cortical excitability in directly stimulated cortical areas (Siebner
and Rothwell, 2003; Powell et al., 2014; Romero Lauro et al., 2014)
and in deeper interconnected brain areas (Strafella et al., 2003,
2004; Pogarell et al., 2007).
Measuring motor evoked potentials (MEP) using TMS
was postulated for the first time to be advantageous in the
management of FW patients by Jellinek et al. (1992). Using a
figure-8 coil placed over the vertex, they performed MEPs of the
first dorsal interosseus muscle for diagnostic purposes in a 25-
year-old man with an acute functional flaccid paraplegia. MEPs
of the paralyzed limb were within the normal range. One week
after diagnostic TMS he experienced a full recovery. The authors
associated the MEP-related muscular activation of the limbs with
his recovery and argued that the patient’s observation of the
brisk (involuntary) limb contraction due to the cortical activation
facilitated the successful symptom management. Schönfeldt-
Lecuona et al. performed the first therapeutic rTMS trial in FW
in 2003 in a patient suffering a right upper limb paralysis leading
to a full and sustained recovery (Schönfeldt-Lecuona et al., 2003).
Our systematic review of the literature was conducted to
identify all published studies that used NIBSmethods for treating
FW patients, and to discuss the potential of NIBS in this disorder.
To achieve this we reviewed all published studies and reports
(articles, published congress abstracts) of the use of TMS [in
every modality: single-pulse(sp)TMS, rTMS including theta-
burst protocol], tDCS and ECT in the treatment of FW affecting
limbs.
METHODS
Search Strategy and Selection Criteria for
the Systematic Review
A literature search was performed using PubMed and Web
of Science databases with the below-elucidated search
strategy. The literature search includes reports published
until the 15 of December 2015. We defined search terms
for the here explored forms of FW and NIBS methods.
The following search terms were used for FW: “conversion
disorder,” “motor conversion disorder,” “conversion weakness,”
“conversion paralysis,” “dissociative weakness,” “dissociative
paralysis,” “dissociative motor symptoms,” “dissociative ∗
plegia,” “psychogenic disorder,” “psychogenic weakness,”
“psychogenic paralysis,” “hysterical weakness,” “hysterical
paralysis,” “hysterical conversion,” “hysterical ∗ plegia,” “non-
organic disorder,” “non-organic weakness,” “non-organic
paralysis,” “non-organic ∗ plegia,” “functional disorder,”
“functional weakness,” “functional paralysis,” “functional ∗
plegia,” “functional neurological symptoms,” and “medically
unexplained neurological symptoms,” [∗plegia, meaning
all forms: mono-, hemi-, para-, tetra-, quadriplegia]. The
following search terms were used for the different types of
NIBS methods explained above: “stimulation,” “stimulation
therapy,” “transcranial magnetic stimulation,” “TMS,” “rTMS,”
“theta-burst∗,” “transcranial direct current stimulation,” “tDCS,”
“electroconvulsive,∗” “electroshock,” and “ECT.”
In a first step, the number of search hits related to each of
the mentioned search terms for FW was retrieved (Figure 1).
In a second step, each of the mentioned search terms related to
FW was linked to all of the mentioned search terms (“AND”)
related to the different types of NIBSmethods (combined search),
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FIGURE 1 | The flowchart delineates the process and the results of the literature search.
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and the respective search hits were checked. Titles and abstracts
related to the retrieved hits identified with the combined search
were then checked manually by two examiners independently
(CSL and MG, see below). In order to detect published
conference and meeting abstracts edited in supplements not
available in PubMed, a second independent search was carried
out in Web of Science with the above mentioned search terms
and then cross-checked. Because of space limitations, only the
PubMed search results are shown in the Figure 1.
Inclusion criteria:
• Therapeutic trials only
• Patients exclusively suffering from FW as described above
• FW patients treated with TMS (in all variants: spTMS, rTMS
including theta-burst TMS), tDCS or ECT
• Any kind of study design: randomized-controlled trials (RCT),
non-RCT, open-label, naturalistic designs; all population sizes
reported were allowed (full study, case series or case report)
Exclusion criteria:
• Non-English, non-German, non-Spanish, non-French
language studies
• Conversion symptoms other than functional weakness or
functional paralysis [non-FW as described here (DSM-5
300.11/ICD-10 F44.4), with or without sensory loss]
• Non therapeutic trial
• Non primary study, duplication, duplicated publication of
data, duplicate patient group
• Insufficient data to evaluate treatment strategy and symptom
outcome
• Disorders of consciousness presented as coma, vegetative state,
minimally conscious state, stupor or catatonia.
Titles and abstracts of the articles retrieved from the combined
search were checked for the presence of data of relevant topics
(see above). Only articles addressing weakness or paralysis
affecting limbs (often also accompanied by loss or reduction
of sensory feeling) were considered. Two examiners (CSL and
MG) then searched the retrieved titles and abstracts by hand and
independently. After retrieval of abstracts fulfilling inclusion-
criteria, full text versions of all identified articles were obtained.
A cross check of the references from retrieved articles was
performed to identify related publications not listed in the
examined databases. Data were extracted independently by
the two authors (CSL and MG). The two data bases were
compared manually and then examined again by both reviewers.
Discrepancies were corrected by reference to the original papers.
Retrospective Reconstruction of the
Clinical Global Impression - Improvement
(CGI-I) Score
From all selected articles, the manuscript content was checked
for clinical descriptions of symptom severity before and after
treatment. The narratives were then used to determine an
approximate change of FW symptoms, using the principles of
the CGI-I scale for a nominal CGI-I score. Narratives were
checked independently by two examiners (CSL and MG) and a
nominal CGI-I score was established. In case of discrepancies,
a consensus decision was reached between the two examiners.
The CGI-I score is a 7-point scale which is commonly used
to describe changes of a patient’s clinical overall improvement
related to a specific treatment. It was developed for use in NIMH
(National Institute of Mental Health)-sponsored clinical trials to
provide a brief, stand-alone assessment of the clinician’s view
of the patient’s global functioning prior to and after initiating a
study (Busner and Targum, 2007). CGI-I comprises the following
categories: 1 = very much improved; 2 = much improved; 3 =
minimally improved; 4 = no change; 5 = minimally worse; 6 =
much worse; 7 = very much worse. If single data were available
a nominal CGI-I was estimated for each patient reported (case
reports and case series). In case of studies not reporting single
data, a nominal CGI-I was calculated for the group of patients
treated with a certain NIBS method.
RESULTS
On December 15, 2015, our literature search resulted in the
following numbers of hits related to the different search terms:
“conversion disorder” n = 2220, “motor conversion disorder” n
= 293, “conversion weakness” n = 174, “conversion paralysis”
n = 21, “dissociative motor symptoms” n = 184, “dissociative
weakness” n = 27, “dissociative paralysis” n = 2, “hysterical
conversion” n = 86, “hysterical weakness” n = 19, “hysterical
paralysis” n = 49, “hysterical paraplegia” n = 15, “functional
weakness” n = 52, “functional paralysis” n = 27, “functional
neurological symptoms” n = 33, “medically unexplained
neurological symptoms” n= 185, “non-organic weakness” n= 9,
“non-organic paralysis” n = 9, “psychogenic weakness” n = 4,
“psychogenic paralysis” n = 25. All in all, the literature search
retrieved 3141 hits. The combined term search led to the results
shown in the Figure 1. The search performed in Web of Science
allowed the identification of one meeting abstract (Kresojevic
et al., 2010) that was not identified using the PubMed database.
We could not retrieve any other relevant publications using Web
of Science, which were not identified using PubMed. Two articles
reported the same patients and therefore had to be excluded
(Schönfeldt-Lecuona et al., 2003; Broersma et al., 2013).
Electroconvulsive Therapy in FW
We identified n = 2 articles in which ECT was performed in
FW (Table 2). In both peer-reviewed articles, a single case was
reported (Giovanoli, 1988; Gaillard et al., 2012).
Case Description
Giovanoli (1988) presented a 61-year old man with a complete
right hand paralysis after superficial laceration of the middle
finger, 11 months duration prior to ECT. Bilateral ECT (Medcraft
B-24) was performed on an outpatient basis 3-times per week
for 2 weeks, then twice weekly for 6 weeks (ECT parameters
not available). Within the first 10 ECT sessions, a progressive
change in color and a decrease in swelling were observed; after the
10th ECT session, approximation of thumb and index finger was
possible; after the 19th ECT edema had disappeared and the hand
exhibited a full range of motion. One week after completion of
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TABLE 2 | Electroconvulsive Therapy (ECT) and Transcranial Magnetic Stimulation (TMS) in functional weakness or paralysis (FW).
Author (year)
Nibs method-study type
Patients and clinical
presentation
Stimulation protocol and technical
data
Symptom development and
efficacy (CGI-I)
Follow-up and other important
issues
Giovanoli, 1988
(ECT)-Case report
Fw pat (male, 61 years),
right hand paralysis, 11
month prior to ect, after
superficial laceration of
middle finger
Ect on outpatient basis. Narcosis with
thiopental sodium (50 mg), atropine (4
mg), and succinylcholine (10 mg).
Bilateral ect (medcraft b-24),
3x/weekly for 2 weeks, then 2x/weekly
for 6 weeks
Progressive improvement from the
first ect in color and skin tone. 1
week after completion fine motor
function of fingers restored (CCI
rating), CGI-I = 2
After 6 month, and after 1 year
patient was not using the hand
any more but it was normal in
appearance (CCI rating), CGI-I =
3
Gaillard et al., 2012
(ECT)-Case report
Fw pat (male 33 years),
quadriplegia, 3 years
prior to ECT
Initially 2–3 ects per week, modality
(ns). Somewhat later 1 ect per week;
than once a fortnight (in order to train
motor skills and maintain mobility). Ect
was performed at increasingly intensity
until a maximum of 1152 mc in order
to reach a seizure of at least 30–40 s
Until the 9th ect the progression in
muscular activity allowed the
patient to perform movements with
increasingly complexity. He gained
progressively more function and
was able to eat without help, and to
manage all activities of daily life in
the perimeter of his room with only
little help. Up to the 25th ect he was
able to walk without help (CCI
rating), CGI-I = 2
Relapse occurred after a while
(ns), with great symptom
fluctuation, dependent on the
momentary circumstances, but
muscular activity remained better
than on admission (CCI rating),
CGI-I = 3
Schönfeldt-Lecuona et al.,
2006
(TMS)-Case series,
open-label
3 FW pat. (1 male) + 1
malingerer. Age mv =
38 years; symptom
duration: 5 weeks to 5
years
F8c, Dantec MacPro X 100, M1
stimulation, 4000 pulses/d, rTMS at
15Hz (2se train, ITI 8 sec), 5 times a
week (working days); I = 110% MT for
the first 2 weeks, then 90% MT for 4 to
12 weeks
All FW improved markedly (CCI
rating)
FW-Pat Nr. 1 CGI-I = 2
FW-Pat Nr. 2 CGI-I = 1
FW-Pat Nr. 3 CGI-I = 2
Improvement sustained at 6 and
12 months (CCI rating)
FW-Pat Nr. 1 CGI-I = 1
FW-Pat Nr. 2 CGI-I = 1
FW-Pat Nr. 1 CGI-I = 2
Chastan and Parain, 2010
(TMS)-Open-label,
retrospective symptom
assessment
70 FW pat., age mv =
24.7 years (8–79);
acute FW in 55 pat.
(median duration 4
days); chronic FW in 15
pat. (median duration
240 days)
Cc, M1 stimulation, 30 pulses every 4
or 5 sec; 1 or 2 session in only 1 day, I
= 100% maximal stimulator output
Immediately or within hours after
rTMS effective in 89% of FW;
ineffective in 11% (CCI rating)
n = 53 pat. (75.7%) CGI-I = 1
n=9 pat. (12.8%) CGI-I = 2
n=5 pat. (7.2%) CGI-I = 3
n = 3 pat. (4.3%) CGI-I = 4
Effect sustained for the majority
after 5 to 6 months. Recurrence
of FW in 8 pat. In those pat.,
repeated rTMS was effective in 6
(CCI rating)
Kresojevic et al., 2010
(TMS)-Case series
1 FW pat. (male 24
years), “hemiparesis
that compromised his
walk.” Duration of
symptoms (ns) 1 PMD
pat. (not entered in the
evaluation)
Cc, vertex stimulation, single rTMS
session with 12 single pulses at initially
30% maximal stimulator output
intensity and increasing I in 10% steps
up to 80% of maximal stimulator
output
“Immediate response, the pat. was
able to walk again independently”
(CCI rating) CGI-I = 2
Recurrence of mild symptoms
after 6 months (partial
deterioration), but mild walk
difficulties did not influence his
daily activities (CCI rating) CGI-I =
3
Gaillard et al., 2012
(TMS)-Case report
1 FW pat. male (33
years), quadriplegia, 6
months prior to rTMS
Coil type and I ns, rTMS at 1 Hz Fr. M1
stimulation, right and left over the
arm-hand area, and right and left over
legs” cortical motor area, 1000 pulses
over each region (total = 4000 pulses
per day), 5 times a week (working
days, over a period of 8 weeks), after
that, twice a week
Progressive amelioration: he was
able to walk again, (rater
impression, CGI-I = 1.5). Further
deterioration led to a new rTMS
treatment causing again symptom
amelioration (CGI-I = 2.5), he was
mobile only with a wheelchair. A
third deterioration led to a new
rTMS (CCI rating), CGII = 2
At follow-up recurrence of FW
occurred (ns); he developed a
phlebitis, pulmonary embolus and
pressure soars, was referred for
ECT (CCI rating), CGI-I = 4
Broersma et al., 2015
(TMS)-placebo-controlled
cross-over, single blinded
11 FW pat. (4 male,
34-65 years), at least a
flaccid hand paralysis;
symptom duration: 4
weeks to 25 years
F8c, Magstim rapid2, contra-lateral
M1 stimulation, 9000 pulses/d, rTMS
at 15Hz (2setrain, ITI 4 sec), 5 times a
week (working days) for 2 weeks; I =
80% MT (11 pat. received active, 8
pat. received placebo rTMS. Placebo
rTMS with an electromagnetic device
(REMP) placed in front of the magnetic
coil at otherwise identical parameters
Primary outcome measure: muscle
strength as measured by
dynamometry; secondary outcome
measure: subjective change in
muscle strength; active rTMS
induced a significantly larger median
increase in objectively measured
muscle strength (24%) compared to
sham rTMS (6%); subjective ratings
showed no statistical difference
between treatments; no CCI rating
No follow-up data available.
pat., patient; F8c, figure-8-coil; Cc, Circular coil; mv, mean value; M1, motor cortex; MT, motor threshold intensity; Fr., Frequency; I, Intensity; d, day; s, seconds; (ns), no specified;
PMD, psychogenic movement disorder; CCI, clinician’s clinical impression; CGI-I, Clinical global impression scale-improvement item: 1 = very much improved; 2 = much improved;
3 = minimally improved; 4 = no change; 5 = minimally worse; 6 = much worse; 7 = very much worse.
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ECT fine motor function of the patient’s fingers was restored (he
was able to button his shirt, tie his shoes and write). At 6 months
follow-up and after 1 year, the patient did not use his hand during
the examination but it was completely normal in appearance. No
specific ECT parameters were stated. CGI-I after ECTwas rated: 2
(much improved). The long-term CGI-I was rated: 3 (minimally
improved).
Gaillard et al. (2012) presented a 33-year old man with
fluctuating quadriplegia, developed 3 years prior to ECT. In total,
35 ECT sessions were performed, initially 2–3 ECT treatments
per week. Subsequently, ECTs were performed less frequently
(first once per week; then once a fortnight) in order to trainmotor
skills and maintain mobility. Until the ninth ECT the progress
in muscular activity allowed the patient to perform movements
with increasing complexity. Progress continued with the patient
gaining progressively more function, being able to eat without
help, and managing all activities of daily living in the perimeter
of his room with little help. Until the 25th ECT he was able
to walk without help. Relapse occurred after a while, with great
symptom fluctuation, dependent on circumstances, but muscular
activity remained better than at admission. ECT was performed
with increasing intensity until a maximum of 1152 mC in order
to reach a seizure of at least 30–40 s. CGI-I after ECT was rated:
2 (much improved). The long term nominal CGI-I was rated: 3
(minimally improved).
Repetitive Transcranial Magnetic
Stimulation (All Variants)
We identified five articles in that TMS/rTMS was performed in
FW affecting limb(s) (Table 2 for characteristics) No articles were
identified reporting theta-burst TMS for the treatment of FW.
Four articles were published in peer-review journals (Schönfeldt-
Lecuona et al., 2006; Chastan and Parain, 2010; Gaillard et al.,
2012; Broersma et al., 2015), and a fifth article was retrieved
from a conference abstract (Kresojevic et al., 2010). Three articles
reported single patients (case reports or case series); only two
articles included a larger sample [n = 70 in Chastan et al.
(Chastan and Parain, 2010) and n= 11 in Broersma et al. (2015)].
Case Description
The study by Schönfeldt-Lecuona et al. (2006) had a prospective
design and a clearly defined stimulation protocol based on
a biological and functional-anatomical etiological hypothesis
(see Discussion). This open-label, non-placebo controlled trial
reported four patients (3 FW, 1 malingerer). Patients received
2 weeks (5-sessions/week) of rTMS in supra-threshold intensity
[110% resting motor threshold (MT)] over the contra-lateral
motor cortex to the paralyzed limb with a focal figure-8 coil
and 4000 stimuli per day. Thereafter, once the patient started
to independently perform own movements of the fingers, sub-
threshold rTMS (90% MT) was continued for 4–12 weeks with
otherwise the same parameters depending on clinical needs. In
all three FW patients rTMS caused a marked amelioration of
symptoms over time that was sustained at 1-year follow-up. The
estimated nominal group-CGI-I after rTMS was rated (for the
3 FW patients): 2 (much improved). The long term CGI-I was
sustained after 1 year at the same level (Table 2 for case related
retrospective calculated CGI-I score).
Gaillard et al. (2012) described the case of a 33-year old man
who had developed a quadriplegia (and anasthesia, December
2004) 6 months before admission. rTMS was performed at 1 Hz
frequency (intensity and coil type not stated) targeting the motor
cortex, right and left, over the arm-hand area, and right and left
over the legs’ cortical motor area (1000 pulses over each region)
with a total of 4000 pulses per day. Initially, treatment was applied
five times a week for 8 weeks, and thereafter twice in a week. The
authors reported marked, progressive symptom amelioration, so
that he was able to walk again. A further deterioration led to a
new rTMS treatment leading again to symptom amelioration (not
otherwise specified), but the patient was then mobile only with
a wheelchair. A third deterioration led to phlebitis, pulmonary
embolism and pressure soars, and ECT was performed (the ECT
performed in this case was illustrated above). CGI-I after the first
rTMS series was rated: 2 (much improved). The long term CGI-I
was rated: 4 (unchanged in relation to rTMS beginning).
Kresojevic et al. (2010) presented two cases treated with
rTMS. One of them (24-year old man) was suffering from a FW
(hemiparesis). This patient was treated in a single session with
12 single pulses using a round coil (at initially 30% maximal
stimulator output intensity and increasing intensity in 10% steps
up to a maximum of 80% stimulator output) over the vertex.
The response to rTMS was stated as immediate (“the patient was
able to walk again independently”). At 6-months follow-up, a
partial deterioration occurred, but he was still able to walk and
minor walking difficulties did not influence his daily activities.
The patients’ CGI-I after TMSwas rated: 2 (much improved). The
long termCGI-I after 6months follow-upwas rated: 3 (minimally
improved).
Chastan et al. (Chastan and Parain, 2010) presented a
retrospective analysis of medical records of 70 FW patients
(26 male), who had received TMS. Fifty-seven percent of the
patients had paraplegia, 37% had a monoplegia, 3% had a
tetraplegia, and 3% a hemiplegia. The stimulation protocol was
variable. The TMS was principally used for routine diagnostic
purposes in each patient. An average of 30 pulses were delivered
at about 0.2–0.25 Hz with a circular coil and an intensity of
100% of maximum stimulator output over the motor cortex
(“opposite the correspondence paralysis or on both sides for
bilateral paralysis,” not otherwise specified). Another session of
30 pulses was sometimes added a few minutes later in case
of incomplete improvement. TMS was very effective in 62
patients, with a dramatic improvement in nine, a total recovery
in 53 (immediately in 43 patients, within minutes or hours in
eight patients, within days in two patients), mild improvement
in five, and no effect in three patients. Acute onset of FW
was associated with a better outcome (but not age, gender or
co-morbid psychiatric disorder). CGI-I after TMS was rated
for each reported patient group: 1 (very much improved) for
the majority of the FW patients (n = 53; 76%); 2 (much
improved) for nine patients (13%); 3 (minimally improved) for
five patients (7%); and 4 (unchanged) for three patients (4%).
Five to six months after TMS, recurrence of FW occurred in
eight patients, six of whom were re-stimulated and responded to
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TMS. There was not sufficient information to calculate long-term
CGI-I.
Broersma et al. (2015) presented the first study using a
placebo-controlled cross-over design and reported 11 patients
with FW with at least a flaccid hand paralysis treated with rTMS.
Based on the stimulation parameters proposed by Schönfeldt-
Lecuona et al. (2006), active rTMS was delivered with a figure-
of-8 coil at 15 Hz over the motor cortex contralateral to hand
paralysis (targeting being guided under neuro-navigation in
seven patients) during 30 min once a day, for a total of 10
working days within 2 weeks (Table 2 for detailed parameters).
The placebo condition consisted of small electrical currents
applied with a real electromagnetic device (REMP) placed in
front of the magnetic coil at otherwise identical parameters.
In the study design, the authors attempted to exclude any
other additional therapeutic influences that could result from
suggestion or afferent feedback due to rTMS-related supra-
threshold muscle contraction. To achieve this goal the authors
performed the active condition at an intensity of 80% of MT,
and the communication with the patients was limited as much
as possible. The stimulation condition switched between active
and sham after the first 2 weeks of stimulation with a wash-out
phase of at least 2 months between both conditions. Because
of dropouts, 11 patients received active rTMS and only eight
patients received sham rTMS. The primary outcome measure
was an objective change in muscle strength as measured by
dynamometry after treatment. The secondary outcome measure
was the subjective change in muscle strength after treatment.
In patients who received both treatments, active rTMS induced
a significantly larger median increase in objectively measured
muscle strength (24%) compared to sham rTMS (6%). Eight out
of 11 patients receiving active rTMS showed an improvement
of at least 20% of muscle strength. However, subjective ratings
showed no statistical difference between treatments, i.e., patients
did not really perceive these objectively measured motor
improvements. As the patients’ muscle strength improved, the
authors suggested that rTMS alone could potentially improve
muscle weakness in FW. However, patients did not report
subjective improved functioning of the affected hand, which
Broersma et al. interpreted as an indication that decreasedmuscle
strength is not the core symptom in FW. They thus propose
that rTMS should be applied as add-on therapy to behavioral
approaches in FW. There was not sufficient information to
calculate nominal CGI-I scores.
Nominal CGI-I Score Reconstruction
For patients treated with rTMS we retrieved sufficient
information from the physician-estimated functional changes
reported in the manuscripts by Schönfeldt-Lecuona et al. (2006)
(n = 3), Chastan et al. (n = 70) (Chastan and Parain, 2010),
Kresojevic et al. (2010) (n = 1), and Gaillard et al. (2012) (n
= 1) that allowed the assessment of 75 FW patients. In the
study by Broersma et al. (2015) the main outcome parameter
was muscular strength changes assessed by dynamometer. The
authors reported that patients were assessed neurologically for
sensory deficits, coordination, reflexes and muscle strength at the
beginning and end of rTMS treatment. However, the narratives
provided in the paper did not allow an estimation of nominal
CGI-I scores. Therefore, these patients (n = 11) were excluded
from the analysis. For patients treated with ECT we retrieved
information from the narratives in the articles by Giovanoli
(1988) and Gaillard et al. (2012) that allowed us to assess the two
patients reported.
For the patients treated with rTMS the estimated scores
showed a satisfactory improvement at the short-term: nominal
CGI-I scores were 1 (very much improvement) in 54 of 75
patients (72%) and 2 (much improvement) in 13 patients (17%).
Only five of the treated patients (7%) improved minimally (CGI-
I = 3), and 3 (5%) remained unchanged (CGI-I = 4). Overall,
about 88% of these patients improved markedly (very much or
much improvement) after stimulations. In no case did patients
worsen in relation to rTMS treatment, and no serious adverse
event was reported. A long-term CGI-I could not be estimated
for the largest study by Chastan et al. (n = 70) (Chastan and
Parain, 2010). FW symptoms recurred in eight patients 5–6
month after rTMS. In 62 patients treatment seem to have caused
some amelioration compared to baseline (not stated). In n =
3 cases by Schönfeldt-Lecuona et al. follow-up CGI-I showed a
sustained amelioration (Schönfeldt-Lecuona et al., 2006), while
in the case by Gaillard the estimated long-term CGI-I was rated
4 (Gaillard et al., 2012). Patients treated with ECT showed a
satisfactory response at short-term follow-up as well (ranging
CGI-I = 2), but a deterioration of FW symptoms at long-term
follow-up (ranging CGI-I= 3 in both cases; Table 2).
DISCUSSION
Discussion of Literature Search Results
We concentrated our search exclusively on limb weakness and
limb paralysis, since other forms of FNS (such as impaired
coordination or balance, dystonia, tremor, myoclonus, fainting,
tics, hemiballismus, chorea, parkinsonism, bizarre gait, astasia,
abasia, aphonia, swallowing difficulty, urinary retention, loss of
touch sensation, double vision, blindness, and deafness) might
have a different neurobiological etiology and probably other
functional-anatomical correlates (Ejareh Dar and Kanaan, 2016).
For this reason, we speculate that differential effects of NIBS
methods might come into play when treating different forms of
FNS.
The literature search identified two case reports with ECT
as treatment for FW (Giovanoli, 1988; Gaillard et al., 2012),
five articles with TMS (Schönfeldt-Lecuona et al., 2006; Chastan
and Parain, 2010; Kresojevic et al., 2010; Gaillard et al., 2012;
Broersma et al., 2015), and none for tDCS, with a total of
86 patients. All identified cases and studies reported a short-
term symptom improvement. However, any assumption of a
beneficial effect of NIBS in FW has to be seen with caution,
as the supporting literature is very sparse and the quality
of the small number of identified articles was poor. Major
concerns when examining the efficacy of NIBS in FW include
the heterogeneity of studies with regard to design and stimulation
parameters (paragraph below for more information), the absence
of randomized controlled conditions in all but one trial, and the
fact that the current literature does not allow a meta-analysis of
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outcome data. Most of the included studies were case reports or
case series (5 out of 7).
Study Designs, Parameters, and Outcomes
For TMS, only one study by Broersma et al. used a
prospective, placebo-controlled, cross-over design with an
objectively measured outcome using a dynamometer (Broersma
et al., 2015). All other identified trials had no sham condition and
only used an unstructured physician oriented clinical impression
as outcome measure. The study with the hitherto largest sample
of 70 patients by Chastan et al. (Chastan and Parain, 2010)
was based on a retrospective sample analysis. Moreover, patients
were mostly stimulated for diagnostic purposes and about 60%
of the patients were children or adolescents. In all studies, FW
symptoms and illness duration of the reported patients were
heterogeneous and data were insufficient for a retrospective
re-analysis, which would have allowed symptom clustering
and meta-analysis. In the five identified articles (Schönfeldt-
Lecuona et al., 2006; Chastan and Parain, 2010; Kresojevic et al.,
2010; Gaillard et al., 2012; Broersma et al., 2015) no detailed
information was presented regarding the way patients were
informed and the treatments explained. The magnitude of the
effect of the explanatory model could therefore not be estimated.
The therapeutic effect of the active rTMS in Broersma et al. (2015)
was smaller than the one reported by others; the mean increase
of muscular strength was only about 20% (dynamometer),
but there was no subjective amelioration of symptoms. The
stimulation intensity in that study was deliberately kept at 80%
MT, and therefore did not trigger any muscle contractions. This
may indicate the importance of the patient becoming aware
of movement and intact motor pathways as part of subjective
symptom improvement. Placebo effects are likely to be involved
in the mechanism of action, since in the study of Broersma, six
out of nine patients showed a slight improvement after sham
rTMS.
The stimulation protocol and parameters used differed
considerably between studies. While most studies used low-
frequency stimulation (1 Hz or less), Schönfeldt-Lecuona et al.
(2006) and Broersma et al. (2015) delivered rTMS with 15 Hz,
considered for rTMS to be high-frequency. Most therapeutic
rTMS were performed in a single session, but the studies by
Schönfeldt-Lecuona et al. and Broersma et al. applied a longer
protocol (over weeks).
Estimated Functional Improvement
Despite some limitations, we retrospectively managed to judge
the efficacy of the investigated stimulation methods (rTMS and
ECT) for treating FW patients using the principles of the CGI-I
scale. In total, we identified 88 patients with FW affecting limbs
that received either rTMS or ECT). For the cases in which
a nominal CGI-I could be retrospectively estimated (n = 77)
about 90% of them improved markedly (very much or much
improvement) after stimulations. Only a minority of the treated
patients improved minimally or remained unchanged. In no
case did patients worsen significantly after treatment and no
serious adverse events were reported. At follow-up, symptom
improvement was not quantifiable in terms of CGI-I for the
majority of the cases (Table 2 for detailed information).
ECT vs. rTMS
To our knowledge only two cases of ECT treatment in FW of
limbs have been published (Giovanoli, 1988; Gaillard et al., 2012)
since this technique was established in psychiatry many decades
ago. Both published cases reported dramatic improvements
of limb movement related to the ECT, thus causing a great
improvement of activity of daily living. Besides the known
favorable effects on brain function in major depression, no
specific mechanism of action has been elucidated for ECT in
relation to FW symptoms. One may speculate that the possible
mechanism for short term gains is the reduction of stress due
to the amelioration of psychological precipitating factors and
an improvement in mood after ECT. A major role of a placebo
effect in both described cases accounting for the symptom
improvement cannot be ruled out. On the other hand, in both
cases improvement was not sustained over time, and both
patients had a partial relapse after a while. None of the cases
postulated or tried a continuation or maintenance ECT, which is
recommended for the treatment of major depression when acute
ECT effects do not persist (Petrides et al., 2011). A disadvantage
of the ECT might be the economical aspect compared with
other NIBS methods; the costs of the general anesthesia and the
required specialized personal are included. Given the risks of
the general anesthesia and (reversible) post-treatment cognitive
disturbances, restriction of ECT to the severest and treatment-
resistant FW cases should be considered.
Most of the included articles were related to TMS/rTMS
(n= 5). rTMS may be the NIBS method that is most appropriate
for the use in limb FW for different reasons: (1) rTMS can
acutely provoke a muscular contraction or transient movements
without needing patients cooperation (or intention) to move.
(2) rTMS is relatively easy to apply in FW. This is in contrast
to stimulations outside the motor cortex for other indications,
in which localization strategies for coil positioning are needed
(Schönfeldt-Lecuona et al., 2005). The magnetic pulses applied
using intensities above MT (supra-threshold stimulation) will
trigger a visually noticeable muscle contraction. Because motor
pathways are intact in FW, this technique allows targeting the
desired motor area with sufficient precision (Herwig et al., 2001,
2003). (3) Longer lasting rTMS causes plasticity changes in brain
areas directly under the magnetic coil (Karabanov et al., 2015),
but also trans-synaptic changes in areas far from the stimulation
site (Strafella et al., 2003, 2004; Pogarell et al., 2007). (4) rTMS
is mostly well tolerated, and has no adverse effects if performed
within safety limits (Rossi et al., 2009). rTMS is considered
not to be painful (depending on the intensity, frequency and
train length of trains applied). (5) rTMS treatment is currently
performed by physicians, but can also be performed by trained
allied medical professionals (nurses, technicians, psychologists).
It does not require any anesthetic, and can be performed in
an outpatient setting. (6) The costs per session are lower than
ECT, and rTMS devises are common nowadays in neurology
and psychiatry departments, and in rehabilitation clinics in many
high-income countries.
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Why Might rTMS Work?
Psychological Aspects
A crucial effect of supra-threshold TMS/rTMS in contrast to
other NIBS methods is the patient’s conscious perception of
the externally triggered movements of their paralyzed limb.
This phenomenon is experienced by all patients treated with
rTMS, since prior to every therapeutic trial, single-pulse TMS
with different intensities will be applied over the motor cortex
in order to establish individual MT. In contrast, tDCS can
modulate the excitability of cortical networks but does not
directly produce action potentials on stimulated networks, and
is therefore unable to trigger muscle contractions. Using ECT
in FW, limb movements are actually provoked through the
induced seizures, but the patient is not capable of noticing
them because ECT is performed under general anesthesia. The
patient’s awareness of the muscle contractions due to TMS may
help through a psychological mechanism: depending on the
information received, patients become aware of normal function
of neuromuscular structures. In addition, TMS triggering of
muscle contraction might make patients aware of the possibility
of regaining function. All identified studies showed an excellent
response to TMS, except the one by Broersma et al. It was in
that study that sub-threshold intensity rTMS was used, which
does no provoke a muscular contraction. In addition, rTMS
bears a high technical and methodological complexity in terms
of technical approaches and calibrating steps that have to be
performed prior to the therapeutic application, especially when
MRI-guided localization techniques for coil positioning are used.
Thus, TMSmay generate a placebo effect, which in turn helps the
patient to recover function immediately after stimulation. The
response to rTMS may also be influenced by the information
received and by the style which was used to inform the patients
about the treatment strategy and purpose.
Neurophysiological Aspects
An increasing body of literature data suggest that focal functional
abnormalities in central networks that control motor cortex
activity may play a role in the etiology of FW (Geraldes et al.,
2008; Liepert et al., 2008, 2009, 2011). The most convincing
hypotheses to explain FW affecting limbs include (i) deficient
processing of either motor intention or disruption between
motor intention and motor execution or (ii) an overactive
self-monitoring with enhanced limbic neural activity, which
interferes with movement planning, and initiation within frontal
regions and thereby disrupting motor execution (Voon et al.,
2011). Studies using functional-imagingmethods in patients with
FW demonstrated enhanced neural activity within the anterior
cingulate area or orbito-frontal cortex and reduced neural activity
within prefrontal motor areas during movement execution of
the paralyzed limb (Marshall et al., 1997; Spence et al., 2000;
Stone et al., 2007). These abnormal activation patterns have
been interpreted to reflect an active, but unconscious inhibition
of movement planning and execution. Focused rTMS protocols
with appropriate stimulation parameters might be able to reverse
cortical dysfunction and restore activity in suppressed cortical
motor areas (Schönfeldt-Lecuona et al., 2003, 2006; Chastan
and Parain, 2010; Nielsen et al., 2013). The stimulation site
for rTMS in FW is usually obvious with the primary motor
cortex being the most plausible candidate region. However, the
most challenging issue is still the choice of stimulation protocol
(frequency, intensity, inter-train intervals, duration, and number
of daily sessions) that can provoke a lasting positive change in
cortical network activity. With regard to the question whether
complementary stimulations in other cortical regions than the
primarymotor cortex could enhance therapeutic efficacy of rTMS
in FW, no studies could be found.
Neuromodulatory Aspects
Single-pulse TMS with short protocols (e.g., performed in only
one session for measuring MEPs for diagnostic purposes) might
not be causing a durable change in cortical activity. Long-
lasting changes and thus changes in cortical neuro-plasticity
might only be induced performing longer protocols (e.g., for
one or more weeks) using high-frequency (>1 Hz) or low-
frequency (≤1 Hz), thus leading to long-term potentiation- or
long-term depression-like changes respectively (Pascual-Leone
et al., 1994; Chen et al., 1997; Fitzgerald et al., 2006). In most
identified trials using TMS in FW, cortical stimulations were
performed using repetitive spTMS with frequencies ≤1 Hz for
a very short time (<2 or 3 min; Chastan and Parain, 2010;
Kresojevic et al., 2010; Gaillard et al., 2012). Therefore, no long-
lasting cortical effects could be expected, nor any stable changes
in motor function due to the used protocols. The immediate
and mostly sustained positive responses to the stimulations
must therefore have other reasons. Only few studies used rTMS
protocols that might potentially cause plasticity changes. We
need to stress that not all of these hypotheses of the mechanisms
of action of rTMS have been translated into proven clinically
relevant changes, and more research is needed to be sure if
they have any clinically meaningful effect (McWhirter et al.,
2015). Furthermore, given that rTMS has existed as a technique
since the 1990s, the number of trials published in this field is
amazingly low. Publication bias could be a partial explanation
for this, as may be the paucity of clinicians considering rTMS in
rehabilitation neurology. However, first rTMS therapeutic trials
have been performed to relieve other forms of FNS such as
dystonia, myoclonus, tremor, parkinsonism, stereotypies, non-
epileptic seizures, functional aphonia, or sensory or visual loss
(Chastan et al., 2009, 2011; Dafotakis et al., 2011; Saha et al., 2011;
Garcin et al., 2013; Parain and Chastan, 2014; Shah et al., 2015),
mostly yielding to symptom amelioration.
RECOMMENDATION IN EVIDENCE-BASED
GUIDELINES AND FUTURE STUDY
DESIGNS
In 2014 evidence-based guidelines on rTMS were published and
included recommendations for “Motor Conversion Disorders” in
general (Lefaucheur et al., 2014). The degree of recommendation
on the efficacy of rTMS for motor conversion disorders was:
“No recommendation for low or high frequency rTMS of M1
or delivered at the vertex, using a focal or a non-focal coil”
(Lefaucheur et al., 2014). The Cochrane library has published
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recommendations for TMS in the treatment of schizophrenia,
depression, obsessive-compulsive disorder, amyotrophic lateral
sclerosis, epilepsy and post-traumatic stress disorder (http://
onlinelibrary.wiley.com/cochranelibrary/), but did not address
the topic of FW. Regarding ECT or tDCS, no sources were
identified that reported evidence-based recommendations for its
use in FW or more generally in FNS. Consistent with previous
recommendations for the publication of case reports or case
series (Lepping et al., 2007), and to allow clinically meaningful
analyses from case series, we recommend that the following
information should be included in any publication:
(1) Regarding devices and targeting procedure: the type of
coil, the type of stimulator, the type of pulse waveform,
the definition of the target and of its localization method,
including the type of navigation system (if used), and the
orientation and angle of the coil. Sham rTMS should be
performed using original sham coils. Other alternatives
should be accurately described and the rationale for the
chosen technique should be highlighted.
(2) Regarding stimulation parameters: the intensity of the
stimulation according toMT (resting/activeMT) ormaximal
stimulator output, the frequency and duration of rTMS
trains, the duration of the inter-train interval, the number of
trains applied, the total number of rTMS pulses per session,
the duration of each session, the number of sessions, the
duration of the interval between the sessions, and the total
duration of the treatment. The rationale for the chosen
treatment protocol should be stated.
(3) Regarding ratings for motor symptoms and quality of life:
the outcome assessment should be at least performed using
CGI-I scores. Limb muscular strength should be assessed
for each muscular group (force rated from 0 = complete
paralysis to 5 = normal strength) at the beginning of
treatment and at follow-up (if possible 6 and 12 months after
cessation of treatment). Objective assessment of muscle force
using dynamometers and of quality of life, using validated
questionnaires are desirable. Raters should be blinded to
the stimulation condition. In addition to objective ratings,
the assessments of the treatment efficacy should include
subjective ratings of symptom severity, as there may be a
disparity between the patient’s and the doctor’s rating.
(4) Regarding the explanatory information for patients, the
information received by the patient about the rTMS
procedure and its expected positive or adverse effects
should be outlined. The given information should be
objective. Explanatory information for patients are not yet
standardized and from a therapeutic perspective, its effect
magnitude on clinical symptoms is unknown.
(5) Regarding a control condition, placebo-controlled study
designs would be highly desirable. However, investigators
should be aware that patients who are not treatment-naïve
would easily detect the difference between the two conditions
(particularly due to the perceptible scalp sensations by
active stimulation). Therefore, except when using special
placebo coils that provoke scalp effects similar to an active
stimulation [as in Broersma et al. (2015) and Rossi et al.
(2007)], we suggest that future studies should either be
designed as parallel-arm studies (avoiding sham detection in
a cross-over design) or as head-to-head studies, comparing
active rTMS with usual therapeutic management of FW.
CONCLUSION
The results of our systematic review provide preliminary
evidence that NIBS methods, especially motor cortex rTMS,
may be beneficial in the treatment of conversion weakness and
paralysis. Most included rTMS studies reported acute beneficial
effects on limb function despite heterogeneous protocols. In
particular, the crucial influence of an externally triggered
muscular contraction should be emphasized. Further rTMS trials
should include a control condition, a greater number of sessions,
and longer stimulation protocols with proven lasting effects on
cortical excitability. However, although advances have beenmade
in the last few years both in diagnostic methods and in the
groundwork for a neurobiological model of FW, no definitive
rationale for stimulation parameters and for the optimal setting
is available. Therefore, further basic research in this area is
needed (Aybek et al., 2008). Probably due to practical aspects
the future of ECT in this area is expected to be less promising
than rTMS. Despite this practical advantage, it remains to be
demonstrated that rTMS can have a real therapeutic benefit
in the long term, and any impact on the neural mechanisms
of FW beyond merely inducing psychological or non-specific
placebo effects. Our systematic review contributes to the current
knowledge of rTMS application in the treatment of FW, updating
the reviews previously published by Pollak et al. (2014) and
Parain and Chastan (2014). In summary, the available evidence
to date suggests that the application of NIBS in FW is feasible
and beneficial. However, due to the small number of published
cases in open-label studies, this conclusion should be considered
with caution.
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